EcoDrugPlus

Janus Kinase 3

Ensembl ID : ENSOANG00000005345
Gene Symbol: JAK3
4 Cross references
103 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOANG00000003803
Gene Symbol: KIT
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSOANG00000037990
Gene Symbol: KRAS
4 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOANG00000001195
Gene Symbol: LCK
2 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOANG00000005501
Gene Symbol: LYN
5 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 2

Ensembl ID : ENSOANG00000007737
Gene Symbol: MAPKAPK2
4 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 5

Ensembl ID : ENSOANG00000009506
Gene Symbol: MAPKAPK5
2 Cross references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOANG00000015031
Gene Symbol: MET
3 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSOANG00000005080
Gene Symbol: NQO1
5 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSOANG00000008867
Gene Symbol: NOX4
4 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSOANG00000039992
Gene Symbol: NFE2L2
4 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOANG00000050736
Gene Symbol: PIM1
2 Cross references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).